Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway

Verteporfin, a FDA approved second-generation photosensitizer, has been demonstrated to have anticancer activity in various tumors, but not including papillary thyroid cancer (PTC). In current pre-clinical pilot study, we investigate the effect of verteporfin on proliferation, apoptosis, cell cycle and tumor growth of PTC. Our results indicate verteporfin attenuates cell proliferation, arrests cell cycle in G2/S phase and induces apoptosis of PTC cells. Moreover, treatment of verteporfin dramatically suppresses tumor growth from PTC cells in xenograft mouse model. We further illustrate that exposure to MEK inhibitor U0126 inactivates phosphorylation of ERK1/2 and MEK in verteporfin-treated PTC cells. These data suggest verteporfin exhibits inhibitory effect on PTC cells proliferation and cell cycle partially via ERK1/2 signalling pathway, which strongly encourages the further application of verteporfin in the treatment against PTC.

• Publication year

  2018

• Venue

  Journal of Cancer

• Publication date

  2018-03-29

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.7150/jca.21915PMID 29721041PMCID 5929076
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• YAP activates the Hippo pathway in a negative feedback loop

  2017cited by this paper
• The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients

  2016cited by this paper
• Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse

  2016cited by this paper
• EDAG-1 promotes proliferation and invasion of human thyroid cancer cells by activating MAPK/Erk and AKT signal pathways

  2016cited by this paper
• Yes-associated protein 1 promotes papillary thyroid cancer cell proliferation by activating the ERK/MAPK signaling pathway

  2016cited by this paper
• NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

  2015cited by this paper
• YAP activates the Hippo pathway in a negative feedback loop

  2015cited by this paper
• Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1

  2015cited by this paper
• Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling.

  2015cited by this paper
• Phosphorylation of myofibrillogenesis regulator‐1 activates the MAPK signaling pathway and induces proliferation and migration in human breast cancer MCF7 cells

  2014cited by this paper
• Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer

  2014cited by this paper
• The Hippo pathway: regulators and regulations.

  2013cited by this paper
• Coordinating developmental signaling: novel roles for the Hippo pathway.

  2012cited by this paper
• Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.

  2012cited by this paper
• Verteporfin‐based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines

  2011cited by this paper
• Defining the therapeutic window of vertebral photodynamic therapy in a murine pre-clinical model of breast cancer metastasis using the photosensitizer BPD-MA (Verteporfin)

  2009influential reference
• Photodynamic therapy with verteporfin: A new treatment in ophthalmology

  2001cited by this paper

• Activating NEDD4L suppresses EGFR-driven lung adenocarcinoma growth via facilitating EGFR proteasomal degradation

  2025cites this paper
• Efficacy of biological inhibitors in three-dimensional culture models of oral squamous cell carcinoma

  2024cites this paper
• Reconstruction of Fibrocartilage with Fibrous Alignment of Type I Collagen in Scaffold-Free Manner

  2023cites this paper
• Repurposed Drugs in Gastric Cancer

  2022cites this paper
• Phosphorylated ATF1 at Thr184 promotes metastasis and regulates MMP2 expression in gastric cancer

  2022cites this paper
• Expression level of long non-coding RNA colon adenocarcinoma hypermethylated serves as a novel prognostic biomarker in patients with thyroid carcinoma

  2021cites this paper
• Verteporfin Promotes the Apoptosis and Inhibits the Proliferation, Migration, and Invasion of Cervical Cancer Cells by Downregulating SULT2B1 Expression

  2020cites this paper
• Verteporfin Is a Promising Anti-Tumor Agent for Cervical Carcinoma by Targeting Endoplasmic Reticulum Stress Pathway

  2020cites this paper
• Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy

  2019cites this paper
• Characterization of Perturbing Actions by Verteporfin, a Benzoporphyrin Photosensitizer, on Membrane Ionic Currents

  2019cites this paper
• Verteporfin suppresses the proliferation, epithelial-mesenchymal transition and stemness of head and neck squamous carcinoma cells via inhibiting YAP1

  2019cites this paper
• ERK1/2 communicates GPCR and EGFR signaling pathways to promote CTGF-mediated hypertrophic cardiomyopathy upon Ang-II stimulation

  2019cites this paper
• Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression

  2019cites this paper
• LncRNA THOR attenuates cisplatin sensitivity of nasopharyngeal carcinoma cells via enhancing cells stemness.

  2018cites this paper